ABL Diagnostics Reveals Expiry of Non-Binding Agreement with ProPhase Labs

On February 19, 2025, ABL Diagnostics S.A., trading on Euronext under the symbol ABLD, announced the conclusion of its non-binding Letter of Intent with ProPhase Labs, Inc. The agreement, initially established with Advanced Biological Laboratories S.A., has expired without the parties pursuing the intended transaction. ABL affirms compliance with existing contractual provisions, with no further disclosure on the matter anticipated.

Dr. Chalom B. Sayada, CEO of ABL S.A., expressed gratitude for the discussions with ProPhase, emphasizing ongoing efforts to facilitate the group’s entry into the United States. The announcement complies with EU Market Abuse Regulation, independently made by ABL Diagnostics. All pertinent information will be archived on the company’s website for regulatory access.